

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Zhou, et al.

Serial No: Not Yet Assigned

Filed: Herewith

For: NOVEL NUCLEIC ACIDS AND  
POLYPEPTIDES


CERTIFICATE OF MAILING  
BY "EXPRESS MAIL" UNDER 37 CFR § 1.10

"Express Mail" Mailing Label Numbers  
EL933683678US

Date of Deposit: January 4, 2002

I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Arlington, VA 22202.

Type or Print Name of Person Mailing: Petrina S. Hsi



Signature of Person Mailing

**PRELIMINARY AMENDMENT**

U.S. Patent and Trademark Office  
Arlington, VA 22202  
Attn: BOX PATENT APPLICATION

Dear Sir:

Prior to substantive examination, please amend the application as follows:

**IN THE SPECIFICATION:**

Please amend the specification as follows:

At page 1, in the Cross Reference to Related Applications, please insert the following sentence after the title: -- This is a divisional of U.S. Application Serial No. 09/620,312, filed July 19, 2000, entitled "Novel Nucleic Acids and Polypeptides", Attorney Docket No. 784CIP2B.--

**IN THE CLAIMS**

Please cancel claims 1-9, 12-19 and 21-28.

Kindly replace pending claims 10 and 20 with the following claims:

10. An isolated polypeptide encoded by the polynucleotide of SEQ ID NO: 482.
20. An isolated polypeptide encoded by the polynucleotide comprising a nucleic acid sequence which is 99% identical to the nucleic acid sequence of SEQ ID NO: 482.

**REMARKS**

Upon entry of the foregoing amendments, claims 10, 11, 20 and 21 are under consideration.

Support for the amendment to claim 10 appears at least in the originally filed claim 10. Support for the amendment to claim 21 appears at least at page 30, line 15 of the specification. Thus, these amendments add no new matter.

**CONCLUSION**

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in a condition for allowance. The undersigned can be reached at 408-746-4536 if the Examiner wishes to discuss the response.

An early action on the merits is respectfully requested.

Respectfully submitted,

Date: January 4, 2002

By: Luisa Bigornia  
Luisa Bigornia  
Attorney for Applicants  
Registration No.: # 45,974  
HYSEQ, INC.  
670 Almanor Avenue  
Sunnyvale, CA 94085  
(408) 524-8100  
(408) 524-8145 (Telefacsimile)

In the Specification:

The specification was amended as follows:

1. CROSS REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. Application Serial No. 09/620,312, filed July 19, 2000, entitled "Novel Nucleic Acids and Polypeptides", Attorney Docket No. 784CIP2B. This application is a continuation-in-part of U.S. Application Serial No. 09/552, 317, filed April 25, 2000, which in turn is a continuation-in-part application of U.S. Application Serial No. 09/488,725, filed January 21, 2000, both of which are incorporated herein by reference in their entirety.

In the Claims:

Claims 1-9, 12-19 and 22-28 were canceled.

Claims 10 and 20 have been amended as follows:

10. (amended) An isolated polypeptide, [wherein the polypeptide is selected from the group consisting of :  
(a) a polypeptide] encoded by SEQ ID No: 482 [any one of the polynucleotides of claim 1; and  
(b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1-877, 879-1104].
20. (amended) An isolated polypeptide [comprising the amino acid sequence selected from the group consisting of any one of the polypeptides from the Sequence Listing, the mature protein portion thereof, or the active domain thereof] encoded by the polynucleotide comprising a nucleic acid sequence which is 99% identical to the nucleic acid sequence of SEQ ID NO: 482.